Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
We have studied the regulation of BDNF mRNA expression in the corticostriatal and nigrostriatal systems following neurotoxin ablation of striatal targets induced by quinolinic acid (QA) or 2S:2'R:3'R:-2-(2'3'-dicarboxycyclopropyl)glycine (DCG-IV) injections. Striatal lesions were verified by quantifying the loss of glutamic acid decarboxylase (GAD) mRNA expression. Levels of BDNF mRNA were analyzed at 6, 12, and 24 h postlesion. Both lesions paradigms highly induced BDNF mRNA in the ipsilateral cerebral cortex at 6 and 12 h postlesion to drop to control levels at 24 h postlesion. These inductions were mostly restricted to cortical layers II/III and V and ipsilateral insular and piriform cortices, which provide the main cortical inputs to the striatum. Analysis of neuronal activation on these areas demonstrated high levels of cFos mRNA in response to the excitotoxic striatal lesions. Dual labeling of cFos and BDNF mRNAs demonstrated a positive correlation between cortical neuronal activation and expression of BDNF mRNA. Consequently, expression of BDNF in cortical areas projecting to striatum is dependent on both target integrity and neuronal activity. Regulation of BNDF mRNA in substantia nigra, the second major source of BDNF to striatal cells, highly differed from that seen in cerebral cortex. Analysis of cellular expression alone or in combination of BDNF, cFos, tyrosine hydroxylase and GAD mRNAs demonstrated that expression of BDNF in substantia nigra is dependent on target integrity and independent of neuronal activity. In addition, we have studied regulatory mechanisms of BDNF mRNA in the subthalamic nucleus.
Rite
Inmaculada
I
Departamento de Bioquímica, Bromatología, Toxicología y Medicina Legal, Facultad de Farmacia, Universidad de Sevilla, C/Prof. García González 2, 41012-Sevilla, Spain.
Machado
Alberto
A
Cano
Josefina
J
Venero
Jose L
JL
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D002540:Cerebral Cortex / Q000378:metabolism* / Q000503:physiopathology; D003342:Corpus Striatum / Q000293:injuries / Q000378:metabolism* / Q000503:physiopathology; D003521:Cyclopropanes; D003714:Denervation; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D005260:Female; D005968:Glutamate Decarboxylase / Q000235:genetics; D005998:Glycine / Q000031:analogs & derivatives*; D006816:Huntington Disease / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D016202:N-Methylaspartate; D009434:Neural Pathways / Q000378:metabolism* / Q000503:physiopathology; D009474:Neurons / Q000378:metabolism; D009498:Neurotoxins; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics; D017378:Quinolinic Acid; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D020813:Receptor, trkB / Q000235:genetics; D013378:Substantia Nigra / Q000378:metabolism* / Q000503:physiopathology; D020531:Subthalamic Nucleus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D019208:Brain-Derived Neurotrophic Factor; D003521:Cyclopropanes; D009498:Neurotoxins; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; C082313:2-(2,3-dicarboxycyclopropyl)glycine; D016202:N-Methylaspartate; D014446:Tyrosine 3-Monooxygenase; D020813:Receptor, trkB; D005968:Glutamate Decarboxylase; D017378:Quinolinic Acid; D005998:Glycine